ArticleBMC pediatrics2026
Clinical characterization and analysis of the SRD5A2 gene in 16 Chinese patients with 5α-reductase type 2 deficiency: a single-center retrospective study.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background5α-reductase type 2 deficiency(5α-RD2) is a rare autosomal recessive disorder primarily caused by variants in the SRD5A2 gene. This condition is characterized by a spectrum of undervirilization in 46, XY individuals, ranging from ambiguous genitalia to predominantly male external genitalia with minimal undervirilization. Early diagnosis and effective management of 5α-reductase type 2 deficiency patients are major challenges for healthcare providers. The mutational analysis of SRD5A2 gene is regarded as the gold standard for the diagnosis of the disease. This study aimed to summarize our center's experience with patients diagnosed with 5α-reductase type 2 deficiency due to variations in the SRD5A2 gene and the associated clinical manifestations to enhance clinicians' awareness of this condition.
methodsWe conducted a retrospective single-center study by reviewing the medical records of patients diagnosed with 5α-reductase type 2 deficiency after genetic testing between April 2018 and July 2025.
resultsAll 16 patients presented with ambiguous genitalia at birth and received diagnoses between the ages of 3 months and 11 years and 3 months. Of these patients, ten exhibited micropenis accompanied by hypospadias, six displayed an isolated micropenis, and six had either bilateral or unilateral cryptorchidism. Additionally, six patients had an underdeveloped scrotum. All affected individuals had a 46, XY karyotype and tested positive for the SRY gene, with two patients initially raised as female. The testosterone/dihydrotestosterone (T/DHT) ratios after human chorionic gonadotropin (hCG) stimulation ranged from 1.5- to 38.6-fold above the baseline values. This study identified ten distinct pathogenic variants of the SRD5A2 gene, including nine previously reported variants p.Gln6Ter, p.Gly66Arg, p.(Tyr128Cys), p.Asn193Ser, p.Gly196Ser, p.Gly203Ser, p.Phe219Serfs*60, p.Arg227Gln, and p.Arg246Gln and one novel variant p.(Cys119Arg), which expands the spectrum of known SRD5A2 variants.
conclusionThis study provides insights into genotype-phenotype correlations in a cohort of 16 Chinese patients diagnosed with 5α-reductase type 2 deficiency and summarized the enzymatic activity of the identified genetic variants. Identifying variants associated with 5α-reductase type 2 deficiency will facilitate genetic counseling for at-risk families and enable prenatal diagnosis, thus empowering parents to make informed decisions and allowing healthcare providers to tailor treatment strategies effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.